Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Share :
Published: 3 Jun 2024
Views: 158
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Dr David Spigel speaks to ecancer at ASCO 2024 about the results from ADRIATIC - a study into durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer.

730 patients were randomised, including 264 to durvalumab and 266 to placebo.

Durvalumab as consolidation treatment after concurrent platinum-based chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival compared with placebo.

Read the full news story here: Durvalumab following chemoradiotherapy improved survival in patients with limited-stage small-cell lung cancer